Neuland Laboratories Share Price

Incorporated on January 7, 1984, Neuland Laboratories Limited (NLL) is promoted by Davuluri Sucheth Rao. The Company is engaged in manufacturing and selling of bulk drugs such as Salbutamol Sulphate, Terbutaline Sulphate, Labetalol Hydrochloride and Ciprofloxacin. Neuland Drugs Pharmaceuticals Pvt. Ltd., a company set up by the same promoters to manufacture bulk drugs was merged with the Company effective from April, 1992. NLL manufactures bulk drugs.The Company came out with its initial public offering in Apr.94 at a premium of Rs 35 aggregating Rs 5.69 cr, to partfinance the capacity expansion to manufacture bulk drugs and to diversify its productmix. The cost of the project as estimated by ICICI was Rs 15.7 cr.NLLs products are exported to more than 35 countries including Germany, Italy, Switzerland, the UK and the Netherlands. The company is also negotiating with multinational companies for tying up supplies of Ranitidine Hydrochloride Form I and Salbutamol Sulphate.During the year 19992000, the company introduced Itraconazole, an antifungal drug and Ipratropium Bromide, an antiasthmatic drug and the R D has developed a process for manufacture of Oflaxacin for Regulatory Markets. The Pashamylaram unit has received USFDA approval for manufacturing of Rantidine Hydrochloride Form.Mirtrazapine, an antidepressive drug and Ramipril a cardiovascular drug were introduced during the year 2001.The installed capacities of Ciprofloxacin and Ranitidine were increased with Rs.650 lacs financial assisitance from IDBI.The Company commenced commercial production of Ramipril, a cardiovascular drug for export to certain markets in 2002.The Company commenced commercial production of Citalopram Hydrobromide, an anti depressant, Pirbuterol Acetate, a bronchodilator, Levofloxacin, an anti bacterial, Levetiracetam, an anti convulsant in 2003.A subsidiary company of Neuland Laboratories Ltd was incorporated on January 4, 2007 in the State of Delaware, USA with its principal office in Orange County, California. During the year 20082009, Neuland Laboratories K.K., Japan was incorporated as a subsidiary of Company.During 201213, Company undertook a major reorganisation of businesses aimed at deleveraging on one hand and on other hand narrowing the focus on core activities: APIs, Intermediates and Contract Manufacturing. Consequently, the Company divested its RD activities by selling its Land and Building and some identified intellectual properties to Neuland Pharma Research Private Limited and its Peptides Research activities along with identified intellectual properties to Neuland Health Sciences Private Limited. It entered into a Joint Business Arrangement with API Corporation, Japan, a part of Mitsubishi Chemical, for manufacturing and sale of APIs and Intermediates.During 201314, the Company enhanced its product bouquet by launching 5 more products. It also enhanced its development portfolio to 22 molecules/ APIs created for launch between 2013 and 2016. It opened new office in New Jersey, provide them with quick support and coordinate in various business activities.In 2018, the Board of Directors of the Company approved the Scheme of Amalgamation of Neuland Health Sciences Private Limited and Neuland Pharma Research Private Limited with the Company, on April 1, 2016, the Appointed Date of Scheme. Pursuant to the Scheme of Amalgamation, 45,90,608 equity shares held by Neuland Health Sciences Private Limited in the Company were cancelled and the Company allotted 68,61,243 equity shares to the shareholders of Neuland Health Sciences Private Limited and Neuland Pharma Research Private Limited on April 13, 2018 and further 1,675,000 equity shares were issued and allotted under Qualified Institutional Placement (QIP). The Company acquired Advanced Intermediates and API facility Unit 3, with a capacity of about 197 kiloliters at Gaddapotharam Village, in Sanga Reddy District, in 201819. The Unit III was commercialised with 320 kL reaction volume in FY 2023.